重庆医学2023，Vol.52Issue(23)：3546-3553,8.DOI:10.3969/j.issn.1671-8348.2023.23.005
ERK5抑制剂XMD17-109通过下调ITPRIP表达抑制胶质瘤进展
ERK5 inhibitor XMD17-109 inhibits glioma progression by down-regulating ITPRIP expression
摘要
Abstract
Objective To investigate the effect of XMD17-109 on the viability of glioma cells and its molecular mechanism based on extracellular signal-regulated kinase 5(ERK5)/inositol 1,4,5-trisphosphate receptor-interacting protein(ITPRIP)signaling pathway.Methods U251 glioma cells were routinely cul-tured,and ERK5 activity was inhibited by XMD17-109.ERK5 knockdown and ERK5 overexpression models were constructed by transfection of RNA fragments and plasmids,respectively.Cells were divided divided into the XMD17-109 group,the Control group,the siERK5 group,the siNC group,siERK5-OE group,the Vector group,the ERK5-OE+XMD17-109 group and the Vector+XMD17-109 group.The cell viability was detected by CCK-8,scratch and flow cytometry experiments and so on.The mRNA and protein expression levels of ERK5 and ITPRIP were detected by reverse transcription-quantitative real time PCR(RT-qPCR)and West-ern blot.Results Compared with the Control group,the cell viability of the XMD17-109 group decreased,and the expression level of ITPRIP decreased(P＜0.05).Compared with the siNC group,the cell viability of the siERK5 group was decreased,and the expression level of ITPRIP was decreased(P＜0.05).Compared with the Vector group,the cell viability of the ERK5-OE group was enhanced,and the expression level of ITPRIP was increased(P＜0.05).Compared the with Vector+XMD17-109 group,the cell viability of the ERK5-OE+XMD17-109 group was enhanced,and the expression level of ITPRIP was increased(P＜0.05).Conclusion XMD17-109 can inhibit the viability of glioma cells by inhibiting ERK5/ITPRIP signaling pathway,which is expected to be a potential drug for glioma treatment.关键词
细胞外信号调节激酶5/肌醇1,4,5-三磷酸受体相互作用蛋白/XMD17-109/胶质瘤/抑制剂Key words
extracellular signal-regulated kinase 5/inositol 1,4,5-trisphosphate receptor-interacting protein/XMD17-109/glioma/inhibitor分类
医药卫生引用本文复制引用
王昕雯,曹长春,朱亮,杜宇,孙增先..ERK5抑制剂XMD17-109通过下调ITPRIP表达抑制胶质瘤进展[J].重庆医学,2023,52(23):3546-3553,8.基金项目
中国博士后科学基金项目(2021M701487). （2021M701487）
